Reuters reports that andexanet alfa, a drug developed by Portola Pharmaceuticals to reverse the bleeding side effects of new oral anticoagulants like Xarelto, has proven successful in a late-stage clinical trial. Portola hopes the new data will help earn the antidote approval from the U.S. Food and Drug Administration.
Xarelto is a relatively new blood thinner that has made strides in the pharmaceutical industry since its introduction in 2011. ...
continue reading...